• Thurs news: Lilly’s weight-loss drug prevents diabetes. Merck pays $588M for bispecific. Amgen speaks out about bone density issues with obesity drug. PTC gets gene therapy approval. JNJ’s 340B legal fight. See more on our front page


We just lost Providence St. Joe's

anonymous

Guest
Holy SH*T!

So we just landed on the Vizient contract - just us and BSC. Not that it matters anymore at PSJH, since we got slapped.

How is it that we allowed BSC to beat us out at PSJH? I mean, was it the fact that we don't have a single-use scope?

Was it them using their POS Ascerta stent to beat our lowball price on Universa?

Maybe it was all of our back orders the last few years?

Should I start looking for a new gig?

Thoughtssssss?
 








We have zero capital, management that hides from customers, higher pricing on products made in the same place in Puerto Rico (different colors though!)....what else you need to know? What we do have has been on backorder for half a decade (literally). Why would providence stay?